![]() Integrated analysis of aortic scRNAseq data (>49,000 cells) identified a continuum of abnormal SMC phenotypic modulation in LDS defined by reduced contractility and enriched extracellular matrix synthesis, adhesion receptors, and transforming growth factor-beta signaling. 4D-MRI demonstrated altered flow parameters in post-operative aortopathy patients relative to controls, but no clear deleterious changes attributable to arch replacement. ![]() Aortic tissues from n=4 LDS patients and n=2 organ donors were processed for anatomically segmented single-cell RNA sequencing (scRNAseq) and histologic assessment.LDS VSARR+arch patients had no deaths, major morbidity, or aortic events in median 2.00 years follow-up. 4D flow magnetic resonance imaging (MRI) studies were performed in n=4 LDS patients (VSARR+arch) and compared with both contemporary Marfan syndrome patients (VSARR only, n=5) and control patients (without aortopathy, n=5). This study assesses the clinical risks and hemodynamic consequences of a prophylactic aortic arch replacement strategy in LDS and characterizes smooth muscle cell (SMC) phenotype in LDS aneurysmal and normal-sized downstream aorta.Patients with genetically confirmed LDS (n=8) underwent prophylactic aortic arch replacement during VSARR. Loeys-Dietz syndrome (LDS) patients demonstrate heightened risk of distal thoracic aortic events after valve-sparing aortic root replacement (VSARR). He is a member of the Society of Thoracic Surgeons, International Society for Minimally Invasive Cardiac Surgery, International Society for Heart & Lung Transplantation, International Society for Heart Research, and other professional societies. He serves on the leadership committee of the American Heart Association’s Council on Cardiovascular Surgery and Anesthesia. He is a fellow of the American College of Surgeons, American College of Cardiology, and American Heart Association. He is the president of the AATS Cardiac Surgery Biology Club. Woo serves on the board of directors of the American Association for Thoracic Surgery (AATS). Woo has co-authored more than 400 articles in peer-reviewed publications. He also has been the primary investigator for translational scientific clinical trials entailing administration of stem cells during coronary artery bypass grafting and left ventricular arterial device (LVAD) implantation. He has served as primary investigator for clinical device trials. Woo has received NIH funding for this study continuously since 2004. One explores stem cells, angiogenesis, tissue engineering, and valvular biomechanics. He serves as principal investigator on two studies funded by National Institutes of Health (NIH) grants. He has advanced these fields by developing innovative surgical procedures. He focuses on complex mitral and aortic valve repair, thoracic aortic surgery, cardiopulmonary transplantation, and minimally invasive surgery. Woo is a board-certified, fellowship-trained heart surgeon with an active clinical practice of more than 300 pump cases per year. Shumway Professor of Cardiothoracic Surgery and holds a courtesy appointment in the Department of Bioengineering. He chairs the Stanford Health Cardiothoracic Surgery Department. Woo is a nationally recognized surgeon, innovator, researcher, and educator in cardiothoracic surgery.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |